Home » Newsletters » BioWorld Science

BioWorld Science

June 29, 2004

View Archived Issues

IRA-01 shows fair antiarthritic effect, good safety and favorable lipid profile

SGN-15 and docetaxel combination promising in non-small cell lung cancer

Licofelone in symptomatic OA of the knee

Statins a potential therapeutic option in glaucoma

Vertex scientists prepare and test new inhibitors of JAK, JNK, CDK, etc.

Novel LTD4 antagonists and their use reported by Almirall Prodesfarma

Two series of MEK/c-Src kinase inhibitors claimed by AstraZeneca

New histamine H3 receptor ligands and their use claimed by Abbott

Oral PTH enters phase I trial under Unigene/GSK collaboration

IND accepted for phase II trials of Aplidin

New phase II trial of MDX-070 in hormone refractory prostate cancer

Millennium reacquires Integrilin European rights, licenses to GSK

Target enrollment met in phase III study of Campath for B-CLL

Closing date of Sanofi-Synthelabo's offer on Aventis postponed to July 30, 2004

Phase IIb trial of tgAAVCF for cystic fibrosis cleared to continue

XL-119 enters phase III trial in bile duct cancer

Change of indications for phase II trials of KOS-862

Singapore study for Dynavax HBV prophylactic vaccine

Sigma-Tau plans phase II European trial of TB4 for venous stasis ulcers

RI-624 enters phase I testing for pain

Positive interim results from phase I study of Davanat-1

Antiinflammatory and cardiovascular benefits found with atorvastatin in rheumatoid arthritis

Add-on therapy with safinamide improves motor function in Parkinson's disease

Therapeutic benefits of adjunctive istradefylline in advanced Parkinson's disease

French team prepares and tests a novel antithrombotic agent

Cyclacel claims new CDK inhibitors for cancer and viral infections

Repinotan study results reported at World Stroke Congress

Study parameters affect preclinical outcomes with neuroprotective agents

Study suggests simvastatin can prevent silent brain infarct

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 30, 2025.
Today's news in brief
Briefs
BioWorld MedTech briefs for Jan. 30, 2026.
Brain-derived tau in blood predicts stroke severity and outcome
BioWorld Science
Brain-derived tau, a protein that is exclusive to the brain and detectable in the blood, could serve as an indicator of brain damage after an ischemic stroke. The...
Centessa’s CNT-9982 shows promise for MDD
BioWorld Science
Orexin OX2 receptor agonists have demonstrated the ability to enhance wakefulness in rodent models, as well as in nonhuman primates and patients with narcolepsy...
First-in-class ADC targeting DEM-TXX shows high preclinical efficacy
BioWorld Science
Researchers at DEM Biopharma Inc. reported preclinical findings demonstrating the efficacy of DEM-301, a bifunctional antibody-drug conjugate (ADC) engineered to...